Si-Bone ( (SIBN) ) has released its Q3 earnings. Here is a breakdown of the information Si-Bone presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SI-BONE, Inc., a leading medical device company specializing in surgical treatments for sacropelvic disorders, continues to make strides in the healthcare sector with its innovative technology and strategic growth plans.
In the third quarter of 2024, SI-BONE reported significant financial milestones, including a worldwide revenue increase to $40.3 million, marking a 19% growth over the previous year. The company also showed a notable improvement in its net loss, reducing it by 34% to $6.6 million. These results highlight the company’s steady progress towards financial health and operational efficiency.
Key highlights from the quarter include the commercialization of the iFuse TORQ TNT device, aimed at addressing pelvic fragility fractures, and the achievement of record numbers in active U.S. physicians using their technology. Additionally, the company successfully refinanced a $36 million term loan, reducing borrowing costs and extending maturity, which underscores its commitment to financial optimization.
Looking ahead, SI-BONE is optimistic about the future, aiming to achieve positive Adjusted EBITDA by the fourth quarter of 2024. The management remains confident in leveraging its established physician base and innovative product lineup to drive sustainable and profitable growth into 2025 and beyond.